ASCO's early returns

Rounding up the winners and losers from ASCO 2015

While discussions about value and incremental data from late-stage checkpoint inhibitors dominated this year's American Society of Clinical Oncology meeting in Chicago, it's clear that investors also were on the lookout for - and willing to reward - early clinical data.

Ignyta Inc. (NASDAQ:RXDX) and ImmunoGen Inc. (NASDAQ:IMGN) were the biggest winners, with gains of more than 60% on Phase I data.

Ignyta's entrectinib led to a 91% objective response rate (ORR) in solid tumor patients

Read the full 771 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE